Alaunos Therapeutics
TCRT
82 hedge funds and large institutions have $2.97M invested in Alaunos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 25 reducing their positions, and 15 closing their positions.
900% more call options, than puts
Call options by funds: $20K | Put options by funds: $2K
0.04% less ownership
Funds ownership: 0.16% → 0.11% (-0.04%)
8% less funds holding
Funds holding: 89 → 82 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
60% less capital invested
Capital invested by funds: $7.36M → $2.97M (-$4.39M)
60% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$35.8K |
| 2 |
Renaissance Technologies
New York
|
+$30.7K |
| 3 |
Morgan Stanley
New York
|
+$13K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$10.7K |
| 5 |
Millennium Management
New York
|
+$8.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$920K |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$145K |
| 3 |
BlackRock
New York
|
-$131K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$75K |
| 5 |
Two Sigma Advisers
New York
|
-$31.7K |
TCRT Hedge Fund Activity: Q4 2023 in Review
82 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2023, worth a combined $2.97M — down 60% from $7.36M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TCRT and 8 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 10 added.
The largest buyer was Squarepoint, opening a new position worth an estimated $35.8K. The largest seller was Discovery Capital Management, cutting an estimated $920K.
- 82 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2023, down from 89 in Q3 2023.
- Funds reported $2.97M of Alaunos Therapeutics stock for Q4 2023, down 60% quarter-over-quarter.
- 8 funds opened new Alaunos Therapeutics positions in Q4 2023 and 15 closed out, a net change of -7 holders.
- The largest Alaunos Therapeutics buyer in Q4 2023 was Squarepoint, an estimated $35.8K added.
- The largest Alaunos Therapeutics seller in Q4 2023 was Discovery Capital Management, an estimated $920K sold.
Based on aggregated 13F filings for Q4 2023.